Coronary revascularization is a key therapeutic strategy in patients with ischemic heart disease. The main objective is to restore blood flow in stenotic coronary arteries, improving myocardial perfusion and reducing the risk of acute ischemic events.
The two main revascularization techniques are:
Percutaneous Coronary Intervention (PCI): A minimally invasive procedure involving dilation of the stenosis with a balloon and implantation of a stent to keep the vessel open.
Coronary Artery Bypass Grafting (CABG): A surgical procedure that creates a vascular bridge (graft) to bypass coronary stenoses, using arteries or veins harvested from the patient.
Indications for Revascularization
The decision regarding revascularization strategy depends on several factors, including the extent of coronary artery disease, left ventricular function, and the presence of symptoms refractory to medical therapy.
The main indications include:
Acute coronary syndrome (STEMI/NSTEMI): Primary PCI or early revascularization based on risk stratification.
Symptomatic stable angina: Revascularization indicated in patients with persistent symptoms despite optimal medical therapy.
Multivessel coronary artery disease: CABG is preferable in patients with left main coronary artery involvement or ventricular dysfunction.
Severe documented ischemia: Need for revascularization in patients with evidence of inducible ischemia in extensive myocardial areas.
Percutaneous Coronary Intervention (PCI)
Percutaneous coronary intervention is a minimally invasive technique that allows treatment of coronary stenoses using a balloon catheter and stent implantation.
Procedure
Vascular access: Generally via the radial or femoral artery.
Balloon dilation: Expansion of the stenosis by controlled inflation.
Stent implantation: Placement of a metallic stent to keep the vessel open.
Types of stents
Bare Metal Stents (BMS)
🛠 Material: Stainless steel, cobalt-chromium, or platinum-chromium.
✅ Advantages: Less need for prolonged antiplatelet therapy, useful in patients at high bleeding risk.
❌ Disadvantages: High risk of restenosis (10-30%) due to neointimal proliferation; now less used compared to DES.
Drug-Eluting Stents (DES)
🛠 Material: Metallic structure (cobalt-chromium or platinum-chromium) with a polymer coating containing antiproliferative drugs (sirolimus, everolimus, zotarolimus, paclitaxel).
✅ Advantages: Significantly reduce the risk of restenosis compared to BMS, available in different generations with improved drugs and polymers.
❌ Disadvantages: Require dual antiplatelet therapy for at least 6-12 months, possible risk of late thrombosis (reduced in latest-generation DES).
Bioresorbable Scaffolds (BRS)
🛠 Material: Biodegradable polymers (polylactic acid - PLLA) or bioresorbable metal alloys (magnesium).
✅ Advantages: Dissolve over time, leaving the artery free from permanent structures, potentially lower risk of long-term complications.
❌ Disadvantages: Larger initial profile, higher risk of thrombosis compared to current DES, limited use due to problems with first generations.
Biodegradable Polymer Stents
🛠 Material: Metallic structure (cobalt-chromium or platinum-chromium) with a biodegradable polymer that releases the drug and then dissolves over time.
✅ Advantages: After drug release, the polymer degrades, reducing inflammation and the risk of late thrombosis.
❌ Disadvantages: Higher cost compared to traditional DES, not yet as widely used as latest-generation DES.
Polymer-Free Drug-Eluting Stents
🛠 Material: Metallic structure (cobalt-chromium or platinum-chromium) with antiproliferative drug incorporated directly into the metal.
✅ Advantages: Eliminate the problem of chronic inflammation associated with polymers, possible reduction in risk of late thrombosis.
❌ Disadvantages: Drug released less controllably than in polymer-based DES, ongoing studies to evaluate long-term efficacy.
Permanently Biocompatible Polymer Stents
🛠 Material: Metallic structure (cobalt-chromium or platinum-chromium) with a biocompatible polymer that does not degrade, but minimizes inflammation.
✅ Advantages: The polymer remains on the metallic structure without causing excessive inflammation, better drug release management.
❌ Disadvantages: Possible minimal risk of chronic inflammation compared to degradable polymers, does not completely eliminate the risk of late thrombosis.
Self-healing Stents (under study)
🛠 Material: Innovative metal alloys with pro-regenerative properties, or biomaterials that promote endothelial healing.
✅ Advantages: Innovative materials that promote endothelial regeneration, potential reduction in restenosis and thrombotic complications.
❌ Disadvantages: Still experimental, high costs, and need for long-term studies.
Drug-eluting stents with biodegradable polymers currently represent the most widely used option for the best balance between safety and efficacy. However, new solutions such as improved bioresorbable stents and polymer-free stents may play an increasing role in the future.
Advantages and disadvantages
Advantages: Less invasive, short recovery times, procedure can be performed in emergencies.
Disadvantages: Risk of restenosis (especially with BMS), need for dual antiplatelet therapy for at least 6-12 months.
Coronary Artery Bypass Grafting (CABG)
Coronary artery bypass grafting is a surgical procedure that creates a new blood flow to bypass coronary obstructions.
Procedure
Graft harvesting: The internal mammary artery, radial artery, or saphenous vein is usually used.
Anastomosis: The graft is connected to the aorta and distally to the coronary artery beyond the stenosis.
Cardiopulmonary bypass: May be used to support the heart during surgery.
Preferred indications for CABG
Three-vessel coronary artery disease with left ventricular involvement.
Critical stenosis of the left main coronary artery.
Failure of PCI or recurrent restenosis.
Advantages and disadvantages
Advantages: Lower risk of restenosis, better survival in patients with extensive disease.
Disadvantages: Invasive procedure, prolonged hospitalization, risk of perioperative complications.
Post-Revascularization Follow-up
After revascularization, adequate follow-up is essential to reduce the risk of restenosis, stent thrombosis (in the case of PCI) or graft occlusion (in the case of CABG), and to prevent new ischemic events.
Monitoring and pharmacological therapy
Dual antiplatelet therapy (DAPT): After PCI, clopidogrel, ticagrelor, or prasugrel + aspirin for at least 6-12 months, according to risk of thrombosis or bleeding. After CABG, aspirin is usually sufficient, but in some cases can be associated with clopidogrel for 12 months.
Risk factor control: Monitoring and management of cholesterol, blood pressure, blood glucose, and lifestyle to reduce the risk of new coronary lesions.
Cardiac rehabilitation: Structured programs of supervised exercise, nutritional support and health education to improve prognosis and quality of life.
Specialist follow-up: Regular cardiology visits with ECG, echocardiogram and stress test to monitor cardiac function and therapy effectiveness.
Long-term aspirin (+ DAPT for 1 year in some cases)
Benefit duration
Risk of restenosis over time, especially with drug-eluting stents
More durable, especially with arterial grafts
Possible need for repeat intervention
High in patients with diffuse coronary artery disease
Rarer, but possible in the long term
Main complications
Stent thrombosis, dissection, bleeding
Infection, stroke, heart failure, graft occlusion
Perioperative mortality
<1% in elective procedures
1-3% (higher in emergency or high risk)
Benefit on survival
Similar to CABG in less complex cases
Better survival in high-risk patients
Emergency approach (AMI/STEMI)
First choice for rapid revascularization
Reserved for selected cases (PCI failure, shock)
Conclusion
The choice between PCI and CABG must be individualized based on the patient's clinical characteristics and the severity of coronary artery disease. Both strategies play a crucial role in the management of ischemic heart disease and must be integrated with optimal medical treatment to achieve the best long-term outcomes.
References
Vrints C, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024;45(36):3415-3526.
Neumann FJ, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87-165.
Patel MR, et al. Appropriate use criteria for coronary revascularization. J Am Coll Cardiol. 2021;78(7):813-834.
Park SJ, et al. PCI versus CABG in left main coronary artery disease. NEJM. 2020;382(2):139-148.
Stone GW, et al. Five-year outcomes with PCI versus CABG in multivessel coronary disease. NEJM. 2019;381(9):799-809.
Gersh BJ, et al. Chronic coronary syndromes: pathophysiology and clinical management. Lancet. 2019;394(10203):939-952.
Knuuti J, et al. Diagnostic imaging in ischemic heart disease. JACC Cardiovascular Imaging. 2022;15(4):455-472.
Douglas PS, et al. Role of non-invasive imaging in the assessment of stable ischemic heart disease. Circulation. 2021;143(10):983-1002.
Ibanez B, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(35):2999-3104.
Fihn SD, et al. ACCF/AHA Guidelines for the management of patients with stable ischemic heart disease. Circulation. 2017;136(12):e1-e65.
